# Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

> **NCT07498335** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (estimated)

## Conditions studied

- Berger Disease
- Bergers Disease
- IgA Nephropathy
- Immunoglobulin A Nephropathy
- Primary IgAN
- Nephritis IgA Type, Nephropathy IgA Type

## Interventions

- **DRUG:** Drug: Atrasentan

## Key facts

- **NCT ID:** NCT07498335
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-02
- **Primary completion:** 2030-11-29
- **Final completion:** 2031-01-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498335, "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07498335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*